OB/GYN Clinical Alert (Vol. 33, No. 3) – July 1, 2016

Read the Disclosure Information Below, then click “Continue” to begin testing.

Release date: July 2016

Valid through: July 2019

Target Audience

This activity is intended for the obstetrician and gynecologist and nurses in OB/GYN practices.

Subjects

  • Prolonged Second Stage of Labor
  • Infection Risk with Same-day Testing and IUD Insertion
  • Still Highly Effective: LNG IUS 52 mg at 7 Years
  • Endocrine-disrupting Chemicals and Female Reproductive Disorders

Objectives

  • Explain the latest data regarding diagnosis and treatment of various diseases affecting women
  • Discuss new data concerning prenatal care, neonatal health, and complications arising in pregnancy and the perinatal period
  • Discuss the advantages, disadvantages, and cost-effectiveness of new testing procedures in women

Credit Available

Physicians

  • Maximum of 2.25 AMA PRA Category 1 Credits

Nurses

  • Maximum of 2.25 nursing contact hours

Sponsor

This activity is sponsored by AHC Media.

Accreditation Statement

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AHC Media is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

Physicians

AHC Media designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

AHC Media is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity has been approved for 2.25 nursing contact hours using a 60-minute contact hour. Provider approved by the California Board of Registered Nursing, Provider #CEP14749, for 27 Contact Hours.

Faculty Listing

Authors

John C. Hobbins, MD, Professor, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora

Rebecca Allen, MD, Assistant Professor, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women and Infants’ Hospital, Providence, RI

Jeffrey T. Jensen, MD, MPH, Leon Speroff Professor and Vice Chair for Research, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland

Robert W. Rebar, MD, Professor and Chair, Department of Obstetrics and Gynecology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo

Editors

Medical Editor: Jeffrey T. Jensen, MD, MPH

Peer Reviewer: Catherine Leclair, MD

Nurse Planner: Marci Messerle Forbes, RN, FNP

Nurse Planner: Andrea O’Donnell, RN, FNP

AHC Media Executive Editor: Leslie G. Coplin

Associate Managing Editor: Jonathan Springston

Financial Disclosure

Jeffrey T. Jensen, MD, MPH reports he is a consultant for Teva Pharmaceuticals and MicroChips; and is a consultant for and receives grant research support from HRA Pharma, Bayer Healthcare, Merck, Agile Pharm, Population Council, AbbVie, Evofem, and ContraMed. Rebecca Allen, MD reports she is a Nexplanon trainer for Merck and a Liletta trainer for Actavis, and she has served on advisory boards for Bayer and Pharmanest. John C. Hobbins, MD and Robert W. Rebar, MD, report no financial relationships relevant to this field of study.

OB/GYN Clinical Alert's Editor, Jeffrey T. Jensen, MD, MPH, reports he is a consultant for Teva Pharmaceuticals and MicroChips; and is a consultant for and receives grant research support from HRA Pharma, Bayer Healthcare, Merck, Agile Pharm, Population Council, AbbVie, Evofem, and ContraMed.

Peer Reviewer Catherine Leclair, MD, Nurse Planners Marci Messerle Forbes, RN, FNP, and Andrea O’Donnell, RN, FNP, Executive Editor Leslie G. Coplin, and Associate Managing Editor Jonathan Springston report no financial relationships relevant to this field of study.

Copyright 2016, AHC Media. All rights reserved.